abstract |
The present invention relates to novel amyloid binding compounds and methods for measuring the effects of the compounds by measuring changes in amyloid plaque levels in living patients. More specifically, the present invention enables the diagnosis of Alzheimer's disease by using the compounds of the present invention as a positron emission tomography (PET /) imaging tracer for studying amyloid deposition in the brain in vivo. Regarding the method. That is, the present invention relates to the use of a novel amyloid-binding compound as a diagnostic agent. The present invention further relates to a method for measuring the clinical efficacy of a therapeutic agent for Alzheimer's disease. Specifically, the present invention relates to novel aryl or heteroaryl substituted pyrazole derivatives, compositions, and therapeutic uses and methods for making these compounds. |